Introduction

Uric acid is a final product of purine nucleoside metabolism in humans, and it is thought that its level is well controlled, mainly by the balance between production in liver from purine nucleosides and excretion into urine. Although its physiological role is poorly understood, uric acid is thought not only to protect neuronal cells due to its antioxidant activity, but also to play a role in maintaining blood pressure [1,2]. It has been suggested that serum uric acid (SUA) should be kept below 7 mg/dL to prevent hyperuricemia, which is a clinically important risk factor for cardiovascular diseases, chronic kidney disease and gout [3,4]. In addition, it is known that several drugs in clinical use alter the level of SUA. For example, angiotensin II receptor blockers such as losartan decrease blood pressure [1,2]. It has been suggested that one-third to one-fourth of uric acid is recovered in the intestinal lumen, while biliary excretion was minimal. Accordingly, direct intestinal secretion was thought to be a substantial contributor to extra-renal elimination of uric acid. Since human efflux transporter BCRP/ABCG2 accepts uric acid as a substrate and genetic polymorphism causing a decrease of BCRP activity is known to be associated with hyperuricemia and gout, the contribution of rBCRP to intestinal secretion was examined. rBCRP was confirmed to transport uric acid in a membrane vesicle study, and intestinal regional differences of expression of rBCRP mRNA were well correlated with uric acid secretory activity into the intestinal lumen. Bcrp1 knockout mice exhibited significantly decreased intestinal secretion and an increased plasma concentration of uric acid. Furthermore, a Bcrp inhibitor, elacridar, caused a decrease of intestinal secretion of uric acid. In Caco-2 cells, uric acid showed a polarized flux from the basolateral to apical side, and this flux was almost abolished in the presence of elacridar. These results demonstrate that BCRP contributes at least in part to the intestinal excretion of uric acid as extra-renal elimination pathway in humans and rats.

Abstract

Urinary excretion accounts for two-thirds of total elimination of uric acid and the remainder is excreted in feces. However, the mechanism of extra-renal elimination is poorly understood. In the present study, we aimed to clarify the mechanism and the extent of elimination of uric acid through liver and intestine using oxonate-treated rats and Caco-2 cells as a model of human intestinal epithelium. In oxonate-treated rats, significant amounts of externally administered and endogenous uric acid were recovered in the intestinal lumen, while biliary excretion was minimal. Accordingly, direct intestinal secretion was thought to be a substantial contributor to extra-renal elimination of uric acid. Since human efflux transporter BCRP/ABCG2 accepts uric acid as a substrate and genetic polymorphism causing a decrease of BCRP activity is known to be associated with hyperuricemia and gout, the contribution of rBCRP to intestinal secretion was examined. rBCRP was confirmed to transport uric acid in a membrane vesicle study, and intestinal regional differences of expression of rBCRP mRNA were well correlated with uric acid secretory activity into the intestinal lumen. Bcrp1 knockout mice exhibited significantly decreased intestinal secretion and an increased plasma concentration of uric acid. Furthermore, a Bcrp inhibitor, elacridar, caused a decrease of intestinal secretion of uric acid. In Caco-2 cells, uric acid showed a polarized flux from the basolateral to apical side, and this flux was almost abolished in the presence of elacridar. These results demonstrate that BCRP contributes at least in part to the intestinal excretion of uric acid as extra-renal elimination pathway in humans and rats.

Citation: Hosomi A, Nakanishi T, Fujita T, Tamai I (2012) Extra-Renal Elimination of Uric Acid via Intestinal Efflux Transporter BCRP/ABCG2. PLoS ONE 7(2): e30456. doi:10.1371/journal.pone.0030456

Editor: Shree Ram Singh, National Cancer Institute, United States of America

Received September 28, 2011; Accepted December 20, 2011; Published February 10, 2012

Copyright: © 2012 Hosomi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was supported in part by Grant-in-Aid for Scientific Research (B) from the Japan Society for the Promotion of Science. No additional external funding received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: tamai@p.kanazawa-u.ac.jp
seen in normal humans. Accordingly, in the present study, we used oxonate-treated rats to estimate the in vivo contribution of extra-renal excretion of uric acid. Furthermore, Caco-2 cells, a well-established model of human intestinal epithelial cells, were used as a model to examine the human intestinal transport mechanism of uric acid.

BCRP/ABCG2 (breast cancer resistance protein) is abundantly expressed at the apical membrane of small intestinal epithelial cells and in liver, and impaired BCRP function is associated with an increase of SUA level [13]. Therefore, in the present study, we focused on the contribution of BCRP to extra-renal clearance of uric acid.

Results

In vivo excretion of externally administered [14C]uric acid in oxonate-treated rats

To estimate the relative contributions of excretory organs, we measured the amounts of recovered radioactivity in urine, bile, and intestinal luminal contents after intravenous administration of [14C]uric acid to oxonate-treated rats with bile duct ligation. The results (percentage of dose) are shown in Table 1. Recoveries of radioactivity in urine, bile, and intestinal luminal contents were 42.6%, 0.68% and 8.90% of the dose, respectively. Although the recovery of radioactivity was not complete, this could be explained by retention of uric acid in the animal body and/or elimination via other routes, such as in expelled air following metabolism in the gut lumen [24]. A rough estimation based on the distribution volume obtained from the plasma concentration-time curve and plasma concentration at the time of measurement (2 hrs after administration) suggested that 4.55% of the dose remained in the body.

Secretion of endogenous uric acid into intestinal lumen in oxonate-treated rats

Direct intestinal luminal secretion of endogenous uric acid was evaluated in closed loops prepared separately from jejunum, ileum, and colon of oxonate-treated rat (Fig. 1A). Uric acid was directly secreted into the intestinal lumen at all segments, and the values of intestinal secretion clearance were 0.49±0.03, 1.58±0.13, and 0.76±0.17 μL/min/cm loop, respectively. Thus, secretory clearance was in the order of ileum˃colon˃jejunum, showing a clear regional difference.

Clearance of endogenous uric acid in oxonate-treated rats

To compare the significance of direct secretion of uric acid from blood to intestinal lumen with excretion into urine and bile, endogenous uric acid clearance was determined in oxonate-treated rats. As shown in Table 2A, urinary and biliary secretory clearances were 0.50 and 0.02 mL/min, respectively, and estimated total intestinal secretory clearance was 0.15 mL/min based on the result of intestinal closed loop assay and intestinal length (Table 2B), assuming that sections of the intestine that were not measured exhibited equal clearance ability. Accordingly, endogenous uric acid is also secreted in a significant amount via the intestine, in the same way as externally administered [14C]uric acid (Table 1).

Identification of transporters involved in intestinal secretion of uric acid

In order to identify the transporter molecules responsible for intestinal secretion, transport of uric acid was directly evaluated using membrane vesicles expressing human (h) and rat (r) transporters hBCRP/rBcrp, hMRP2/rMrp2, and hMDR1. As shown in Fig. 2A, in hBCRP- and rBcrp-expressing membrane vesicles, uptake of uric acid in the presence of ATP was

| Table 1. Recovery of [14C] uric acid up to 120 min in oxonate-treated rats. | Urine | Bile | Intestine | Bile+Intestine |
|---|---|---|---|---|
| Cp × Vz | 4.55% | 42.58% | 0.68% | 8.90% | 9.58% |

Recovery of [14C] uric acid was determined in oxonate-treated rats after intravenous administration of [14C] uric acid (2 μCi/rat). Each value is the mean of 4 to 9 measurements.

doi:10.1371/journal.pone.0030456.t001

| Table 2. Clearance of endogenous uric acid in oxonate-treated rats. | Clrenal | Clbile | Clintestine, estimated |
|---|---|---|---|
| 0.50±0.06 | 0.02±0.002 | 0.15 |

Clearance of endogenous uric acid was measured in oxonate-treated rats. Urine, bile and blood were collected up to 60 min and clearances were calculated by dividing the amount excreted into each part by plasma AUC. Estimated intestinal clearance was obtained as described in Materials and methods using mean value of 5 individual measurements; 118±2.52 cm for length for jejunum and 15.7±0.33 cm for colon, respectively. Values indicate mean ± S.E.M. (n = 5).
doi:10.1371/journal.pone.0030456.t002
significantly higher than that in the presence of AMP. Slight ATP-dependent uric acid uptake was observed with rMrp2, whereas hMRP2 and hMDR1 were inactive (Fig. 2A). These results indicated that uric acid is a substrate of rBcrp as well as hBCRP, and also, to a minor extent, rMrp2. Subsequently, uric acid transport by rBcrp was further characterized. Saturation kinetics determined Km value and Vmax as 12.5 ± 0.77 mM and 67.3 ± 4.21 nmol/5 min/mg protein, respectively (Fig. 2B), although maximum concentration of uric acid was 5 mM due to its low solubility. Low affinity of uric acid to rBcrp which was characterized Km value of 12.5 mM, was very comparable to that to hBCRP (Km = 8.24 mM). Additionally, rBcrp showed similar sensitivity to inhibitors with human BCRP as shown in Fig. 2C.

To further determine if rBcrp contributes to intestinal secretion of uric acid in rats, the influence of an inhibitor of hBCRP/rBcrp, elacridar [35], on uric acid uptake by rBcrp-expressing membrane vesicles and intestinal secretion was examined by the in situ closed ileal loop method. Because MDR1 does not transport uric acid, altered transport of uric acid by elacridar, which is a strong inhibitor for both MDR1 and BCRP, can be attributed to its inhibitory effect on BCRP activity (Fig. 2A). The results are shown in Figs. 1A and 3. In the presence of 10 μM elacridar, intestinal secretory clearance was significantly decreased to 0.27 ± 0.04 (55%) of that in elacridar-untreated rats, 0.82 ± 0.12 (52%), and 0.23 ± 0.04 (30%) μL/min/cm loop in jejunum, ileum, and colon, respectively (Table 1A). Interestingly, the regional difference of intestinal secretion of uric acid tended to be associated with the regional difference of mRNA expression levels of rBcrp, which was most highly expressed in ileum (Fig. 1B). Furthermore, ileal secretion of uric acid was inhibited to 53% and 34% of the control in the presence of 0.1 and 10 μM elacridar, respectively (Fig. 3A). Such an inhibitory effect of elacridar on ileal secretion of uric acid was comparable to the effect on Bcrp1 knockout mice.

Plasma uric acid and intestinal clearance in oxonate-treated wild-type and Bcrp1 knockout mice

To examine the in vivo contribution of Bcrp1 to intestinal secretion of uric acid, we measured endogenous uric acid in plasma and evaluated its intestinal secretion by means of the intestinal closed loop method in wild-type and Bcrp1-knockout (Bcrp1−/−) mice. As shown in Fig. 4A, plasma uric acid level was much higher in Bcrp1−/− mice compared with wild-type mice after oxonate treatment. In addition, the intestinal secretory (0.61 ± 0.08 μL/min/cm) and renal clearance (16.0 ± 1.77 μL/min) of endogenous uric acid in Bcrp1−/− mice was significantly lower than those in wild-type mice (1.04 ± 0.11 μL/min/cm, and 23.5 ± 1.42 μL/min), respectively (Fig. 4B, C). Accordingly, it was

![Figure 2. Uric acid transport by ABC transporters.](https://www.plosone.org/doi/10.1371/journal.pone.0030456.g002)
is thought to be predominantly due to BCRP in humans because uric verapamil (an inhibitor for MDR1). Accordingly, secretory transport was significantly reduced in the presence of

\[ u > \text{Control, open bar} \] and presence of 0.1 (gray bar) or 10 (black bar). Each bar indicates the mean ± S.E.M. (n = 4–8). An asterisk (*) shows a significant difference from uric acid uptake in the absence of

elacridar by Student’s t-test (p < 0.05). (B) Uptake of \([^{14}C]\)uric acid (20 pm) by membrane vesicles was measured for 5 min at 37°C in the presence (Control, open bar) and presence of 0.1 (gray bar) or 10 pm elacridar (closed bar). Each bar shows the mean ± S.E.M. (n = 3–6). An asterisk (*) shows a significant difference from uric acid uptake in the absence of elacridar by Student’s t-test (p < 0.05).

doi:10.1371/journal.pone.0030456.g003

demonstrated that Bcrp contributes at least in part to the intestinal secretion of uric acid.

Transcellular transport of uric acid in Caco-2 cells

To examine whether uric acid is secreted into gut lumen via BCRP in humans, we studied transcellular transport of uric acid in Caco-2 cells (Table 3). Secretory transport of uric acid across Caco-2 cell monolayer was more than two-times greater than absorptive transport (1.73 ± 0.11 vs. 0.81 ± 0.02 \((10^{-6} \text{ cm/sec})\)), and such polarized transport was significantly reduced in the presence of elacridar (an inhibitor for both MDR1 and BCRP), Ko143 (a potent inhibitor for BCRP) and MK571 (an inhibitor for MRPs), but not verapamil (an inhibitor for MDR1). Accordingly, secretory transport is thought to be predominantly due to BCRP in humans because uric acid is unlikely a substrate of MDR1 and MRPs (Fig. 2A).

Discussion

In this study, we investigated the contribution and molecular mechanism of extra-renal elimination of uric acid. Since elevated SUA has been reported to be associated with several diseases [3,4], an understanding of the mechanism of uric acid disposition is important in order to control SUA level. In humans, it is reported that two-thirds of uric acid is excreted from kidney, while the rest is recovered in feces [24]. In order to examine whether uric acid is eliminated into intestinal lumen in rats, as it is in humans, we firstly measured the extent of \(^{14}C\) recovery after intravenous injection of \([^{14}C]\)uric acid in oxonate-treated rats as a model animal (Table 1). Uric acid was excreted into bile and intestinal lumen in addition to urine, and most of the uric acid is secreted directly into the intestinal lumen from blood, not via the bile ducts, as an extra-renal elimination pathway.

In order to confirm that intestinal luminal secretion is the major extra-renal elimination pathway, we further evaluated intestinal secretion of endogenous uric acid by means of the in situ intestinal closed loop method in oxonate-treated rats (Table 2 and Fig. 1A). The estimated total intestinal clearance was 0.15 mL/min (Table 2), which was less than the urinary excretion clearance, 0.50 mL/min, but much larger than the biliary excretion clearance, 0.02 mL/min. The relative contribution of extra-renal excretion versus urinary excretion was comparable to that in the case of \(^{14}C\) recovery in vivo (Table 1). This demonstrates a significant contribution of intestinal secretion to extra-renal elimination. Furthermore, endogenous uric acid was secreted from blood directly into the intestinal lumens at all intestinal segments, and the secretion at the ileum was about three- to four-times greater than in the jejunum and colon, respectively (Fig. 1A).

Then, we examined the molecular mechanism(s) of extra-renal excretion of uric acid into intestinal lumen. Recently, Matsuo et al. reported that genetic polymorphisms resulting in decreased BCRP activity in humans are associated with an elevated SUA level, resulting in an increased incidence of gout [36]. BCRP is expressed in the apical membrane of proximal tubular cells in humans [29], suggesting that it plays a role in urinary excretion of uric acid. Since BCRP expression is much higher in the intestinal epithelial cells and hepatocytes than in proximal tubular cells [37], we compared the roles of BCRP and other transporters, MRPs, and MDR1, in extra-renal excretion of uric acid. These transporters are well-characterized efflux transporters for xenobiotics and drugs in both intestine and liver. Uric acid was transported by hBCRP/BCRP and rMrp2, but not by hMrp2 or hMDR1 (Fig. 2). Since rMdr1a-expressing membrane vesicles were not available, we examined bidirectional transport of uric acid in LLC-PK1 cells expressing rMdr1a; however, no significant difference between secretory and absorptive transport of uric acid was observed (data not shown). Accordingly, it appears that uric acid is a substrate of Bcrp, as well as hBCRP [18,36], and Bcrp and BCRP mediate uric acid secretion directly into the intestinal lumen and via the bile duct. In further study, rBcrp-mediated transport of uric acid was strongly inhibited by elacridar, Ko143 and estrone-3-sulfate, and moderately by benzbromarone, MK571, rifampicin and cyclosporin A, respectively, but was not affected by ketoprofen and salicylic acid (Fig. 2C). These results are in agreement with the previous observations in hBCRP-mediated transport [35,38,39]. Furthermore, the \(K_m\) value of uric acid by Bcrp, 12.5 mM, was relatively close to that by hBCRP, 8.24 mM [36]. Accordingly, uric acid transport by BCRP shows similar characteristics between human and rat. Because rMrp2 is expressed in the bile canalicular membranes and intestinal apical membrane [40,41], rMrp2, but not hMrp2, may also be involved in intestinal secretion of uric acid.

Since Bcrp was suggested to mediate uric acid secretion into the intestinal lumen, the effect of the rBcrp inhibitor elacridar was examined. Secretion of endogenous uric acid into the intestinal lumen was significantly reduced in the presence of 10 pm elacridar at all intestinal segments (Fig. 1A). Furthermore, the inhibitory potential of elacridar on the uric acid uptake in rBcrp-expressing vesicles was comparable to that on the intestinal clearance of uric acid at rat ileum. Additionally, the mRNA expression level of rBcrp in each segment was comparable with the regional differences of intestinal secretion in the segments (Fig. 2). These findings strongly indicated that Bcrp is at least involved in the direct secretion of uric acid from intestines.

To further obtain evidence that Bcrp contributes to intestinal secretion of uric acid, we employed intestinal closed loop assay of oxonate-treated Bcrp\(^{−/−}\) mice. Plasma uric acid was significantly higher in Bcrp\(^{−/−}\) mice and lethal secretory clearance of uric acid was significantly lower in Bcrp\(^{−/−}\) mice, as compared with
wild-type mice. These results confirmed that Bcrp is an important player in uric acid disposition. However, in rodents, Bcrp1 expression in kidney relative to intestine and liver is reported to be comparable [30]. Therefore, urinary excretion of uric acid was also reduced as well as intestinal secretion in Bcrp1−/− mice. Further, a compensatory mechanism may operate in Bcrp1−/− mice, because the SUA level should be kept constant physiologically in rodents as well as in humans. Indeed, no significant change of SUA level was observed in mice lacking the uric acid reabsorptive transporter Urat1 [42]. Therefore, it may not be reasonable to evaluate the quantitative contribution of Bcrp based only on the results in transporter-gene deficient mice.

Finally, we evaluated the intestinal secretion of uric acid in humans using Caco-2 cells as a model of human intestinal epithelial cells. Secretory transport of uric acid across Caco-2 cell monolayer was greater than its absorptive transport, and such polarized transport was abolished in the presence of elacridar, Ko143 and MK571 (Table 3). These results imply that uric acid is secreted into the intestine through the intestinal epithelial cells in human as well as rat, and this process could be mediated by an efflux transporter BCRP in human. Since MK571 and verapamil were reported to slightly inhibit BCRP [35], uric acid transport might be reduced by them. Unexpectedly, bidirectional transport of uric acid was dramatically reduced in the presence of MK571, which inhibits effectively MRP members. Although further clarification of the mechanism should be warranted, this observation may involve other transporters in uric acid transport expressed in Caco-2 cells rather than BCRP, such as MRP4, which is a putative uric acid transporter.

Our results indicate that extra-renal excretion of uric acid amounts to at least one-fourth of urinary excretion in rats, which is comparable with the contribution in humans, and this process cannot be ignored in considering uric acid disposition. Furthermore, the direct intestinal secretion of uric acid was much greater than biliary excretion, suggesting that extra-renal elimination of uric acid mainly involves direct secretion into the gut lumen through the intestinal epithelial cells from blood, but not through the bile ducts. In humans, it has been reported that the uric acid concentration in bile is 1–2 mg/dL, and biliary clearance is 0.1–0.3 mL/min [43]. Therefore, biliary excretion of uric acid should be a minor contributor to the extra-renal elimination pathway in humans as well as in rats, because urinary clearance is about 5.8–6.3 mL/min in humans [44,45]. Furthermore, it was directly demonstrated for the first time that hBCRP/rBcrp is likely to contribute to intestinal and biliary excretion of uric acid.

### Table 3. Transcellular transport and the effect of elacridar on uric acid transport in Caco-2 cells.

| Condition       | Permeability (×10⁻⁶ cm/sec) | Efflux ratio |
|-----------------|-----------------------------|--------------|
|                 | AP to BL                    | BL to AP     |               |
| Control         | 0.81±0.02                   | 1.73±0.11    | 2.13±0.19     |
| ≥2 μM elacridar | 0.86±0.06                   | 0.88±0.04*   | 1.02±0.05*    |
| +1 μM Ko143     | 0.83±0.01                   | 1.07±0.04*   | 1.26±0.01*    |
| +100 μM verapamil| 0.84±0.05                  | 1.29±0.13    | 1.55±0.16     |
| +10 μM MK571    | 0.73±0.02*                  | 0.81±0.05*   | 1.11±0.06*    |

Transcellular transport of uric acid in Caco-2 monolayer was measured in the absence or presence of elacridar (2 μM), Ko143 (1 μM), verapamil (100 μM) and MK571 (10 μM) at 37 °C and pH 7.4. The ratio was obtained by dividing BL-to-AP permeability by AP-to-BL permeability. The values indicate mean ± S.E.M. (n = 3). An asterisk (*) and shows a significant difference from the control by Student’s t-test (p<0.05).

doi:10.1371/journal.pone.0003456.t003

---

**Figure 4. Plasma uric acid concentration and its intestinal and renal clearance in oxonate-treated mice.** (A) Plasma uric acid concentration, (B) intestinal clearance at the ileum, and (C) renal clearance were measured in oxonate-treated wild-type (open symbols) and Bcrp1−/− (closed symbols) mice by means of the intestinal closed loop method and metabolic cages. Each value indicates the mean ± S.E.M. (n = 4–5). An asterisk (*) shows a significant difference from wild-type mice by Student’s t-test (p<0.05).

doi:10.1371/journal.pone.0030456.g004
Accordingly, it may be possible to decrease the SUA level in hyperuricemia/gout patients by enhancing intestinal elimination of uric acid through activation of BCRP function. It has been reported that sevelamer, a non-absorbable hydrogel, adsorbs uric acid nonselectively in the gastrointestinal tract, and decreases SUA in humans [46,47]. This is consistent with the idea that the SUA level can be controlled by enhancing secretion of uric acid into intestinal lumen.

Materials and Methods

Chemicals and animals

[14C]Uric acid (1.96 TBq/mol) was purchased from Moravek Biochemicals, Inc. (Brea, CA, U.S.A.). Elacridar and potassium oxonate were purchased from Toronto Research Chemicals (North York, Ontario, Canada) and Kanto Chemicals (Tokyo, Japan), respectively. All other reagents were purchased from Sigma-Aldrich (St. Louis, MO, U.S.A.), Wako Pure Chemical Industries, Ltd. (Osaka, Japan), Nacalai Tesque (Kyoto, Japan), and Applied Biosystems (Foster City, CA).

All the animal studies were approved by the Committee of Kanazawa University for the Care and Use of Laboratory Animals and were carried out in accordance with its guideline for the Care and Use of Laboratory Animals (AP-111937, AP-111938 and MN0687). Six-week-old Wistar rats were purchased from Sankyo Labo Service Corporation, Inc. (Tokyo, Japan). For the Bcrp1−/− mouse study, mice were obtained from Taconic Inc. (Hudson, NY).

In vivo animal study

Male Wistar rats (280±30 g body weight) used in the present study were treated with potassium oxonate, a uric acid oxidase (uricase) inhibitor. Oxonate-treated rats were established as described previously [34,48]. Briefly, rats were anesthetized with 50% urethane (2 mL/kg) and infused with 0.9% NaCl, 0.5% oxonate and 4% mannitol solution from the femoral vein at the flow rate of 3 mL/hr. As a bolus, 0.9% NaCl, 1.5% oxonate and 4% mannitol solution was administered from the jugular vein at 6 mL/kg. After equilibration for 80 min, blood, urine and bile samples were collected at 20-min intervals. When [14C]uric acid (2 μCi/rat) was used, it was intravenously injected from the jugular vein after oxonate treatment for 80 min. In order to suppress the uricolytic activity of [14C]uric acid by intestinal flora [24], animals received orally non-absorbed antibiotics, polymyxin B, kanamycin, and vancomycin at daily doses of 30, 50 and 20 mg/kg, respectively, for 7 days before this animal study. Urine and bile were collected at 20-min intervals, and blood samples were drawn at 1, 5, 10, 20, 40, 60, 80, 100 and 120 min. Urine and bile were collected from bladder and bile ducts, respectively, and blood from the jugular vein. In mice, urine was collected for 24 hours by using metabolic cages (Natsume, Tokyo, Japan).

Intestinal luminal secretion study by in situ intestinal closed loop method

We evaluated intestinal secretion of endogenous uric acid according to the method described previously, with some modifications [49]. Rats were anesthetized with 50% urethane and treated with oxonate by the same method as in the in vivo animal study described above. Intestinal closed loops were made at different segments: jejunum (10 cm), ileum (10 cm), and colon (3–5 cm). Phosphate-buffered solution (PB, 0.075 M NaH2PO4 - 0.075 M Na2HPO4, pH 6.5) or inhibitor-containing PB was injected into the intestinal loop. After 60 min, the remaining luminal content in each loop was washed out and collected for quantitation. Blood was obtained from the jugular vein at 1, 20, 40 and 60 min. Plasma was obtained by centrifugation and used for quantitation.

Mice were treated with oxonate (intraperitoneal injection of 200 mg/kg oxonate in 1% arabic gum solution) at 1 hr before injection of PB solution into the intestinal loop. Blood was withdrawn from the jugular vein at 1, 30 and 60 min. At 60 min, the intestinal luminal content was collected for measurement of intestinally secreted uric acid.

The following equation was used to calculate intestinal secretory clearance (µL/min/cm loop) and estimated total intestinal secretory clearance (CLintestine, estimated) (mL/min):

\[
\text{Intestinal clearance (CL}_{\text{intestine}} = \frac{A_{\text{Loop}}}{\text{AUC}_{0-60}}
\]

\[
\text{CL}_{\text{intestine, estimated}} = \frac{\{1/2 \times (V_{\text{Jejunum}} + V_{\text{Ileum})} \times L_{\text{Jejunum + Ileum}}\} + (V_{\text{Colon}} \times L_{\text{Colon}})}{\text{AUC}_{0-60}}
\]

\[
V_{\text{Loop}} = \frac{A_{\text{Loop}}}{60 \times L_{\text{Loop}}}
\]

where A is the amount of uric acid secreted into the intestinal lumen of each loop for 60 min, L is the length of the intestine, and AUC is area under the plasma concentration-time curve.

Transport study in membrane vesicles

hBCRP/rBcrp, hMRP2/rMrp2, or hMDR1-expressing membrane vesicles prepared from SF9 cells were purchased from GenoMembrane Inc. (Yokohama, Japan). Uptake experiments were conducted as described previously [50]. Briefly, after a pre-incubation for 5 min at 37°C, membrane vesicles (50 µg protein/50 µL final reaction volume) were incubated for 5 min at 37°C in the presence of 4 mM ATP or AMP in assay buffer (1 M KCl, 1 M MgCl2, and 100 mM MOPS-Tris, pH 7.0) containing [14C]uric acid (1 µCi/mL). The uptake reaction was terminated by adding 1 mL ice-cold washing buffer (1 M KCl, and 100 mM MOPS-Tris, pH 7.0) to the membrane solution, and the mixture was rapidly filtered through a nitrocellulose filter (0.45 µm pore size, Millipore, Bedford, MA). The filters were washed twice with 5 mL ice-cold washing buffer. The filters were dried and dissolved in Celsol-I for quantitation of radioactivity.

Bidirectional trans-cellular transport study in Caco-2 cells

Caco-2 cells were obtained from the American Type Culture Collection (Rockville, MD). Caco-2 cells were cultured in Dulbecco's modified Eagle's medium (D-MEM) (Invitrogen, Carlsbad, CA) supplemented with 10% (v/v) fetal bovine serum (Invitrogen), 100 units/mL benzylpenicillin, 100 µg/mL streptomycin, 1% (v/v) MEM non-essential amino acid solution (Invitrogen) at 37°C under an atmosphere of 5% CO2 in air. For bidirectional transport studies, Caco-2 cells were cultured on Transwell filter membrane inserts (BD Falcon, surface area 0.9 cm2 and pore size 3 µm) at a density of 6×104 cells/cm2 for 21 days before use for each experiment. Transport measurement was initiated by adding transport medium (5.36 mM KCl, 136.89 mM NaCl, 0.34 mM Na2HPO4·7H2O, 0.44 mM KH2PO4, 4.17 mM NaHCO3, 1.26 mM CaCl2, 0.49 mM MgCl2·6H2O, 0.41 mM MgSO4·7H2O, 19.45 mM glucose, 10 mM HEPES/Tris, pH 7.4) containing [14C]uric acid to the
donor side and transport medium without \(^{14}\text{C}\text{H}_{2}\text{O}_{4}\) uric acid to the receiver side. Inhibitor was added to only apical side. Transport of \(^{14}\text{C}\text{H}_{2}\text{O}_{4}\) uric acid was measured in two directions, namely apical (AP)-to-basal (BL) and BL-to-AP directions. An aliquot of transport buffer was obtained from the donor side at 5 min for measurement of initial concentration, and from the receiver side at 30, 60, 90 and 120 min. Transport studies were performed at 37°C and pH 7.4.

The apparent permeability \(P_{\text{app}} \text{ cm/sec} \) of \(^{14}\text{C}\text{H}_{2}\text{O}_{4}\) uric acid across the cell monolayer was calculated using the following equation:

\[
P_{\text{app}} = \frac{\frac{dQ}{dt}}{A \times C_d}
\]

where \(Q\) is the amount of \(^{14}\text{C}\text{H}_{2}\text{O}_{4}\) uric acid transported over time \(t\). \(C_d\) is the initial concentration in the donor side and \(A\) is the surface area of membrane.

Real-time reverse transcription polymerase chain reaction

Total RNA was prepared from intestinal mucosa by using standard methods. Single-strand cDNAs were synthesized with a High Capacity cDNA Reverse Transcription Kit (Invitrogen). Relative quantification of rat Bcrp and rat glyceroldehyde 3-phosphohydrogenase (Gapdh) mRNA expression was performed with a Real-Time PCR system (MX3000p, Stratagene, Cedar Creek, TX) using Brilliant SYBR Green QPCR Master Mix and Reference Dye (Stratagene) with 35 cycles of denaturation at 95°C for 15 sec, annealing at 58°C for 20 sec, and extension at 72°C for 20 sec. The expression level was normalized to that of rat Gapdh. The sequences of gene-specific primer pairs were follows: forward and reverse primers for Bcrp were 5'-TTGGATAAAGGGCGACCTC-3' and 5'-AGCTTTTGAG-AGCGAAGAG-3', respectively, and for Gapdh were 5'-GGTGGGTCACATGGGCTTCA-3' and 5'-ATTGTGAGGGGAGA-TCCCTGAGTG-3', respectively.

Analytical methods

Concentrations of uric acid in plasma, urine, bile, and intestinal content were analyzed by means of HPLC. Briefly, 80 μL 0.41% HClO\(_4\) was added to 40 μL of sample and mixed well. The sample was kept 4°C for 30 min. An aliquot was centrifuged at 15,000 rpm for 5 min at 4°C to separate denatured proteins. Eighty μL of the supernatant was mixed with an equal amount of 200 mM Na\(_2\)HPO\(_4\) solution, and then a portion (50 μL) was applied to the HPLC system (Alliance 2690/UV/VIS Detector 486, Waters,Milford, MA). The HPLC analysis was performed using Mighysil RP-18 GP 5 μm (250 mm×4.6 mm, Kanto Chemical Co, Tokyo, Japan) as an analytical column at 50°C. The mobile phase was composed of 40 mM Na\(_2\)HPO\(_4\) (pH 2.55)/methanol (99/1), delivered at a flow rate of 1 mL/min. The retention time was about 7.0–7.5 min. Uric acid was detected at 284 nm. The calibration curve was linear over the range of 0.25–50 mg/L.

All data are presented as the mean ± S.E. Statistical significance was evaluated with Student’s t-test with \(p<0.05\) as the criterion for a statistically significant difference.

Author Contributions

Conceived and designed the experiments: AH TN TF IT. Performed the experiments: AH. Analyzed the data: AH IT. Contributed reagents/materials/analysis tools: TF. Wrote the paper: AH TN IT. Research: IT.  

References

1. Hopper DC, Scott GS, Zborck A, Mikheeva T, Kean RB, et al. (2000) Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis. FEBS Lett 14: 691–696.
2. Masuo K, Kawaguchi H, Miki H, Oghara T, Tuck ML (2003) Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 42: 474–480.
3. Alderman MH, Grossman E, Jelakovic B, Jacovides A, Bernhardi DC, et al. (2000) Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination on oxypurine metabolism in healthy subjects. Intern Med 41: 793–797.
4. Uchino H, Tamai I, Yamashita K, Minemoto Y, Sai Y, et al. (2000) Identification and characterization of human glucose transporter-like protein-9 (GLUT9). Alternative splicing alters trafficking. J Biol Chem 16: 16229–16236.
5. Manolis MJ, Grossman E, Jelakovic B, Jacovides A, Bernhardi DC, et al. (2000) Effects of losartan and candesartan combination on oxypurine metabolism in healthy subjects. Intern Med 41: 793–797.
6. Enomoto A, Takeuchi M, Shinoda M, Narikawa S, Kobayashi Y, et al. (2002) Interaction of human organic anion transporter 2 and 4 with organic anion transport inhibitors. J Pharmacol Exp Ther 301: 797–802.
7. Takeda M, Mamada H, Anzai N, Shirasaka Y, Nakanishi T, et al. (2010) Renal secretion of uric acid by organic anion transport 2 (OAT2/SLC22A2) in human. Biol Pharm Bull 33: 498–503.
8. Uchino H, Tamai I, Yamashita K, Minemoto Y, Sai Y, et al. (2000) Identification of a utate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci U S A 106: 10338–10342.
25. Sorensen LB, Levinson DJ (1975) Origin and extrarenal elimination of uric acid in man. Nephron 14: 7–20.
26. Sato M, Wakayama T, Mamada H, Shirasaka Y, Nakanishi T, et al. (2011) Identification and functional characterization of uric acid transporter Urat1 (Slc22a12) in rats. Biochem Biophys Acta 1808: 1441–1447.
27. Li Y, Sato M, Yanagisawa Y, Mamada H, Fukushima A, et al. (2008) Effects of angiotensin II receptor blockers on renal handling of uric acid in rats. Drug Metab Pharmacokinet 23: 263–270.
28. Bheth S, Hess SK, Firoz D, Thorens B, Gearing K, et al. (2009) Mouse GLUT9: evidence for a urate uniporter. Am J Physiol Renal Physiol 297: F612–619.
29. Huls M, Brown CD, Windass AS, Sayer R, van den Heuvel JJ, et al. (2008) The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. Kidney Int 73: 220–225.
30. Tanaka Y, Saito M, Kawachi M, Chia SH, Suzuki Y, et al. (2002) Immunolocalization of multispecific organic anion transporters, OAT1, OAT2, and OAT3, in rat kidney. J Am Soc Nephrol 13: 848–857.
31. Jutabha P, Kanai Y, Hosoyamada M, Chairoungdua A, Kim DK, et al. (2003) Identification of a novel voltage-driven organic anion transporter present at apical membrane of renal proximal tubule. J Biol Chem 278: 27980–27988.
32. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, et al. (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61: 3458–3464.
33. Matsson P, Pedersen JM, Norinder U, Bergstrom CA, Artursson P (2009) Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters Pgp, BCRP and MRP2 among registered drugs. Pharm Res 26: 1816–1831.
34. Matsuo H, Takada T, Ichida K, Nakamura T, Nakayama A, et al. (2009) Common defects of ABCG2, a high-capacity urate exporter, cause of gout: a function-based genetic analysis in a Japanese population. Sci Transl Med 1: 1–8.
35. Pogunke M, Hazai E, Fromm MF, Zelik O (2010) Drug transport by breast cancer resistance protein. Expert Opin Drug Metab Toxicol 6: 1363–1384.
36. Nicholls A, Snaith ML, Scott JT (1971) Uric acid clearance in patients with gout and normal subjects. Ann Rheum 30: 285–289.
37. Eraly SA, Vallon V, Rieg T, Gangouyi JA, Wikoff WR, et al. (2008) Multiple organic anion transporters contribute to net renal excretion of uric acid. Physiol Genomics 33: 180–192.
38. Shinosaki T, Yonetani Y (1991) Hyperuricemia induced by the uricosuric drug probenecid in rats. Jpn J Pharmacol 55: 461–468.
39. Shibue Y, Fukuyama Y, Yoshida K, Fukuda H, et al. (2011) Quantitative time-lapse imaging-based analysis of drug-drug interaction mediated by hepatobiliary transporter, multidrug resistance-associated protein 2, in sandu-washed rat hepatocytes. Drug Metab Dispos 39: 894–901.
40. Tsuji A, Terasaki T, Tamai I, Hikita M, Hikita M, et al. (1987) H+ gradient-dependent and carrier-mediated transport of cefoxitin, a new cephalosporin antibiotic, across brush-border membrane vesicles from rat small intestine. J Pharmacol Exp Ther 241: 594–601.